- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06426836
Pædiatrisk antibiotikadosering ved ekstrakorporal membraniltning (PADECMO) (PADECMO)
Pædiatrisk antibiotikadosering ved ekstrakorporal membraniltning
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Pieter De Cock, PharmD
- Telefonnummer: +32 9 332 29 69
- E-mail: pieter.decock@uzgent.be
Studiesteder
-
-
-
Ghent, Belgien, 9000
- Rekruttering
- University Hospital
-
Kontakt:
- Pieter De Cock
- E-mail: pieter.decock@uzgent.be
-
Leuven, Belgien, 3000
- Rekruttering
- Universitair hospital
-
Kontakt:
- Debaveye Yves
- E-mail: yves.debaveye@uzleuven.be
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgien, 1020
- Rekruttering
- Queen Fabiola Children's University Hospital
-
Kontakt:
- Biarent Dominique
- E-mail: dominique.biarent@huderf.be
-
Kontakt:
- Vens Daphne
- E-mail: daphnevania.vens@huderf.be
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Exclusion Criteria:
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Amoxicillin-clavulanate
Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Andre navne:
|
|
Andet: Piperacillin-tazobactam
Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
Andre navne:
|
|
Andet: Meropenem
Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving meropenem as part of routine clinical care.
Andre navne:
|
|
Andet: Cefazolin
Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving cefazolin as part of routine clinical care.
Andre navne:
|
|
Andet: Vancomycin
Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving vancomycin as part of routine clinical care.
Andre navne:
|
|
Andet: Teicoplanin
Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving teicoplanin as part of routine clinical care.
Andre navne:
|
|
Andet: Ciprofloxacin
Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
Andre navne:
|
|
Andet: Amikacin
Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amikacin as part of routine clinical care.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Tidsramme: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Tidsramme: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Tidsramme: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Tidsramme: up to 1 month
|
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Tidsramme: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tidsramme: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tidsramme: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Tidsramme: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Tidsramme: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Tidsramme: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Tidsramme: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Tidsramme: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300 |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Tidsramme: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Tidsramme: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399 |
up to 1 month
|
|
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Tidsramme: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Tidsramme: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Tidsramme: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Tidsramme: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Tidsramme: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tidsramme: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Annick de Jaeger, MD, University Hospital, Ghent
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Peptider
- Aminosyrer, peptider og proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Farmaceutiske præparater
- Undersøgelsesteknikker
- Håndtering af eksemplar
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Kulhydrater
- Glycosider
- Amider
- Aminoglycosider
- Glycoconjugates
- Lægemiddelkombinationer
- Penicillin g
- beta-lactams
- Lactams
- Clavulansyre
- Clavulansyrer
- Cephalosporiner
- Thiazines
- Fluoroquinoloner
- 4-quinolones
- Quinolones
- Quinoliner
- Sulfoner
- Carbapenems
- Thienamycins
- Tazobactam
- Penicillansyre
- Piperacillin
- Glycopeptider
- Ampicillin
- Penicillins
- Kanamycin
- Lipoglycopeptider
- Amoxicillin
- Meropenem
- Piperacillin, Tazobactam lægemiddelkombination
- Vancomycin
- Amikacin
- Cefazolin
- Amoxicillin-Kalium Clavulanat kombination
- Teicoplanin
- Ciprofloxacin
- Blodprøveopsamling
Andre undersøgelses-id-numre
- BC-03512 (EC 2015/0529)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .